APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_11
APP DESCRIPTION: SkinTrack lets patients photograph their moles monthly and stores standardized images. No AI — the app just prompts the photo and shows past photos side-by-side. If size/color changes by more than a threshold, the app suggests booking a dermatologist appointment. EU market.

DEVELOPER PERSONA: Indie founder, dermatology-curious, single-person team.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D3, P1.D4, P1.D5, P2.D1, P2.D3, P4.D3, P4.D4, P5.D2, P6.D2, P7.D1

TRANSCRIPT:
### USER
SkinTrack lets patients photograph their moles monthly and stores standardized images. No AI — the app just prompts the photo and shows past photos side-by-side. If size/color changes by more than a threshold, the app suggests booking a dermatologist appointment. EU market.

### ASSISTANT
Does SkinTrack use any biometric data to uniquely identify patients, such as facial recognition or fingerprint scanning, to match users to their records? [card_gdpr_biometric · p.0]

### USER
Honestly I treat SkinTrack as a wellness photo-diary, not a medical device, so I haven't registered it or gone near a Notified Body. I know it nudges people to 'see a dermatologist' when a mole's size or color changes past my threshold, but to me that's just a reminder, not a diagnosis.

### ASSISTANT
Does SkinTrack store or access any information on users' terminal devices, such as through cookies, SDKs, or trackers, which would trigger ePrivacy Art. 5(3)? [card_eprivacy_terminal · p.0]

### USER
There's been no real usability testing or onboarding beyond the consent screen and a data-export demo — the only user research is me using it myself. I haven't written guidance on which moles to track or how often, so usage is totally up to the user.

### ASSISTANT
Does SkinTrack use any third-party SDKs, trackers, or analytics tools that could trigger ePrivacy Art. 5(3) by accessing or storing information on users' devices? [card_eprivacy_terminal · p.0]

### USER
I haven't really thought through edge cases like a brand-new mole appearing, a mole the user stops photographing, or unusual skin tones and bad photos. The app just compares what it has and stays silent if it doesn't have a good baseline.

### ASSISTANT
Does SkinTrack collect, process, or retain any biometric data (e.g., facial features, skin texture, or mole characteristics) that could fall under GDPR Art. 9, and if so, does it have a valid legal basis for doing so? [card_gdpr_biometric · p.0]

### USER
These are mole photos with location and date, which is GDPR special-category health data, but I'm a one-person shop so I haven't done a formal data protection assessment or mapped this against the Article 9 special-category rules. My consent screen mentions photos, locations and notes are stored, but it doesn't spell that out.

### ASSISTANT
Does SkinTrack's handling of health data (e.g., mole photos, dates, and locations) meet the requirements of GDPR Art. 9(2)(a) — explicit consent — by providing clear, specific, and granular information about the purpose of processing and the data being collected, and allowing users to withdraw consent as easily as they gave it? [card_gdpr_art9 · p.0]

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### ASSISTANT
Does SkinTrack's consent mechanism for health data (mole photos, location, date, user-marked changes, and optional symptom notes) meet the GDPR Art. 9(2)(a) requirement for **explicit, granular, and specific consent**, with clear information about the purpose of processing and the data collected, and with an equally easy mechanism for withdrawal? [card_gdpr_art9 · p.0]

### USER
I'll admit if the app stays quiet a user could read that as 'my moles are fine' and skip their normal dermatology check-ups. We don't have any wording that warns people not to treat a no-alert state as an all-clear.

### ASSISTANT
Does SkinTrack's lack of explicit warnings about the limitations of its monitoring function — such as not treating the absence of alerts as an indication that moles are benign — risk misleading users and thereby violate the **principle of data minimization** under GDPR Art. 5(1)(c) and the **principle of transparency** under GDPR Art. 13(1)? [card_gdpr_base · p.0]

### USER
There's no clinical study or validation behind it at all. The 20% area-change threshold that triggers the 'see a doctor' suggestion is a number I picked myself, with no dermatology evidence base or expert review, so I can't tell you how many real melanomas it'd catch or how many false alarms it throws.

### ASSISTANT
Does SkinTrack's use of a self-defined 20% area-change threshold for triggering a "see a dermatologist" suggestion meet the **clinical validity** requirement under [P2.D3] of the HERA taxonomy, and does it risk violating the **clinical evaluation** obligations under MDR Art. 61 and MDCG 2020-1, given that it is classified as a **medical device software** (SaMD) under the EU MDR? [card_clinical_eval_mdsw · p.0]

### USER
Threshold for 'see a doctor' set arbitrarily at 20% area change. No clinical basis.

### ASSISTANT
Does SkinTrack's arbitrary 20% area-change threshold for triggering a "see a dermatologist" suggestion risk violating the **clinical evaluation** obligations under MDR Art. 61 and MDCG 2020-1, and could this lack of clinical validation expose the app to regulatory action under [P2.D3] of the HERA taxonomy, which relates to **clinical validity** and **clinical evaluation**? [card_clinical_eval_mdsw · p.0]

### USER
Post-market I only have crash analytics and no clinical incident workflow, so there's no process for checking whether my threshold actually works once it's live — no clinical audit, no outcome tracking. I'd have no way of knowing if the app missed something it shouldn't have.

### ASSISTANT
Does SkinTrack's lack of a **post-market clinical surveillance** plan, including **clinical incident reporting** and **outcome tracking**, violate the **post-market surveillance (PMS)** obligations under MDR Art. 100 and MDCG 2020-10, and could this absence of a PMS framework expose the app to regulatory action under [P2.D4] of the HERA taxonomy, which relates to **post-market clinical follow-up** and **risk management**? [card_pms_lifecycle · p.0]

### USER
We don't have a prominent disclaimer explaining that this is just photo storage and pixel comparison, not a medical assessment. I can see how a user might assume it's medical-grade and more clinical than it really is.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Risk Report for SkinTrack**  
*Structured by HERA Pillar & Dimension, with severity levels (High, Medium, Low)*  

---

### **P1. Legal & Regulatory Compliance**  
**[P1.D1] Data Protection by Design & Default**  
- **Risk**: SkinTrack lacks a formal data protection impact assessment (DPIA) for health data processing under GDPR Art. 30 and Art. 35.  
- **Severity**: High  
- **Mitigation**: Conduct a DPIA for health data processing, including risk assessment for data minimization, purpose limitation, and security measures [GDPR Art. 30, 35].  

**[P1.D2] Consent for Health Data**  
- **Risk**: Consent mechanism does not meet GDPR Art. 9(2)(a) for explicit, granular, and specific consent.  
- **Severity**: High  
- **Mitigation**: Revise the consent screen to clearly state the purpose of processing, data collected, and the right to withdraw consent [GDPR Art. 9(2)(a)].  

**[P1.D3] Clinical Evaluation & Validity**  
- **Risk**: Arbitrary 20% area-change threshold lacks clinical validation, violating MDR Art. 61 and MDCG 2020-1.  
- **Severity**: High  
- **Mitigation**: Conduct clinical validation studies with dermatology experts to establish a scientifically justified threshold [MDR Art. 61, MDCG 2020-1].  

**[P1.D4] Post-Market Surveillance (PMS)**  
- **Risk**: No PMS plan, incident reporting, or outcome tracking, violating MDR Art. 100 and MDCG 2020-10.  
- **Severity**: High  
- **Mitigation**: Develop a PMS plan with incident reporting, PMCF, and PSUR for Class IIa/IIb/III classification [MDR Art. 100, MDCG 2020-10].  

---

### **P2. Clinical & Technical Safety**  
**[P2.D1] Clinical Validity & Effectiveness**  
- **Risk**: No clinical validation of the 20% threshold, risking misdiagnosis or missed melanomas.  
- **Severity**: High  
- **Mitigation**: Engage dermatologists to validate the algorithm and threshold, ensuring alignment with clinical guidelines [MDR Art. 61, MDCG 2020-1].  

**[P2.D2] Transparency & User Awareness**  
- **Risk**: No disclaimer clarifying that the app is not a medical assessment, risking user misunderstanding.  
- **Severity**: Medium  
- **Mitigation**: Add a prominent disclaimer stating the app is for photo storage and pixel comparison, not medical diagnosis [GDPR Art. 13(1)].  

**[P2.D3] Risk Management & Clinical Evaluation**  
- **Risk**: No clinical evaluation process or risk management plan, violating MDR Art. 61 and MDCG 2020-1.  
- **Severity**: High  
- **Mitigation**: Implement a clinical evaluation process with risk analysis and mitigation strategies [MDR Art. 61, MDCG 2020-1].  

---

### **P3. Ethical & Social Responsibility**  
**[P3.D1] User Autonomy & Informed Consent**  
- **Risk**: Lack of warnings about the limitations of the app’s monitoring function, risking user misinterpretation.  
- **Severity**: Medium  
- **Mitigation**: Add explicit warnings that the absence of alerts does not imply safety, and encourage regular dermatology check-ups [GDPR Art. 13(1)].  

**[P3.D2] Equity & Accessibility**  
- **Risk**: No consideration for unusual skin tones or poor photo quality, potentially leading to false negatives.  
- **Severity**: Medium  
- **Mitigation**: Include guidelines for users on how to capture high-quality images and consider diverse skin tones in testing [MDR Art. 100].  

---

### **P4. Security & Data Integrity**  
**[P4.D1] Data Security & Confidentiality**  
- **Risk**: No formal data protection assessment or security measures for storing health data.  
- **Severity**: High  
- **Mitigation**: Implement encryption, access controls, and regular security audits to protect health data [GDPR Art. 30, 35].  

**[P4.D2] Data Minimization**  
- **Risk**: Storage of unnecessary health data (e.g., location, date) without justification.  
- **Severity**: Medium  
- **Mitigation**: Limit data collection to what is strictly necessary for the app’s purpose [

Now produce the JSON judgement object.